Senescence: A new weapon for cancer therapy

Trends in Cell Biology

Volumn 22, Issue 4, 2012, Pages 211-219

  Acosta, Juan Carlos ^a   Gil, Jesús ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Myc; P53; Ras; Secretome; Senescence; Therapy; Tumor suppressors

Indexed keywords

2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; CVT 2584; CYCLIN DEPENDENT KINASE INHIBITOR; CYSTEINE RICH PROTEIN 61; I BET 151; IMATINIB; IMETELSTAT; JQ1; MIRA 1; MLN 4924; MYC PROTEIN; NUTLIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRIMA 1; TELOMERASE; UNCLASSIFIED DRUG; VO OHPIC;

CANCER INHIBITION; CELL ACTIVATION; CELL AGING; CELL CYCLE ARREST; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AGING; ANIMALS; CELL AGING; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 84859265162     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2011.11.006     Document Type: Review

References (88)

1. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25:585-621.
2. Carrel A., Burrows M.T. On the physicochemical regulation of the growth of tissues: the effects of the dilution of the medium on the growth of the spleen. J. Exp. Med. 1911, 13:562-570.
3. Kurz D.J., et al. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 2000, 113:3613-3622.
4. Narita M., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
5. Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 2009, 9:81-94.
6. Coppe J.P., et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
7. d'Adda di Fagagna F., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
8. Collado M., et al. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
9. Kuilman T., et al. The essence of senescence. Genes Dev. 2010, 24:2463-2479.
10. Lazzerini Denchi E., et al. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Cell. Biol. 2005, 25:2660-2672.
11. Chen Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
12. Michaloglou C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
13. Braig M., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
14. Collado M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
15. Gray-Schopfer V.C., et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br. J. Cancer 2006, 95:496-505.
16. Quintanilla M., et al. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986, 322:78-80.
17. Sun P., et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308.
18. Bennecke M., et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010, 18:135-146.
19. Carragher L.A., et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol. Med. 2010, 2:458-471.
20. Sarkisian C.J., et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 2007, 9:493-505.
21. Lee K.E., Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010, 18:448-458.
22. DeNicola G.M., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
23. Goel V.K., et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009, 28:2289-2298.
24. Dankort D., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41:544-552.
25. Dhomen N., et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
26. Reimann M., et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272.
27. Smith L.L., et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011, 8:649-662.
28. Acosta J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
29. Alimonti A., et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 2010, 120:681-693.
30. Courtois-Cox S., et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
31. Young A.P., et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol. 2008, 10:361-369.
32. Shamma A., et al. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 2009, 15:255-269.
33. Sage J., et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
34. Dirac A.M., Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 2003, 278:11731-11734.
35. Sawyers C.L. Making progress through molecular attacks on cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:479-482.
36. Gray-Schopfer V., et al. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
37. Chang B.D., et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
38. Chang B.D., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999, 59:3761-3767.
39. Schmitt C.A., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
40. Serrano M., Blasco M.A. Cancer and ageing: convergent and divergent mechanisms. Nat. Rev. Mol. Cell Biol. 2007, 8:715-722.
41. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
42. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
43. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
44. Chin L., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
45. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8:167-179.
46. Malumbres M., et al. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol. Sci. 2008, 29:16-21.
47. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
48. Campaner S., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol. 2010, 12:54-59.
49. Lin H.K., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
50. Puyol M., et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
51. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080.
52. Luo J., et al. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
53. Wu C.H., et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13028-13033.
54. Soucek L., et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 1998, 17:2463-2472.
55. Soucek L., et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
56. van Riggelen J., et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev. 2010, 24:1281-1294.
57. Zuber J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
58. Delmore J.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
59. Dawson M.A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
60. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006, 13:921-926.
61. Ventura A., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
62. Xue W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
63. Ancrile B., et al. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
64. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
65. Kang T.W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
66. Jun J.I., Lau L.F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 2010, 12:676-685.
67. Krizhanovsky V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
68. Sharpless N.E., DePinho R.A. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 2007, 8:703-713.
69. Popov N., Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 2010, 5:685-690.
70. Visel A., et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010, 464:409-412.
71. Minamino T., Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ. Res. 2007, 100:15-26.
72. Baker D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
73. Haugstetter A.M., et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br. J. Cancer 2010, 103:505-509.
74. Mann D.M., et al. Binding of soluble fibronectin and its subsequent incorporation into the extracellular matrix by early and late passage human skin fibroblasts. J. Biol. Chem. 1988, 263:2756-2760.
75. Sottile J., et al. Regulation of collagenase and collagenase mRNA production in early- and late-passage human diploid fibroblasts. J. Cell. Physiol. 1989, 138:281-290.
76. Millis A.J., et al. Collagenase production by early and late passage cultures of human fibroblasts. Exp. Gerontol. 1989, 24:559-575.
77. Murano S., et al. Diverse gene sequences are overexpressed in werner syndrome fibroblasts undergoing premature replicative senescence. Mol. Cell. Biol. 1991, 11:3905-3914.
78. Zeng G., Millis A.J. Expression of 72-kDa gelatinase and TIMP-2 in early and late passage human fibroblasts. Exp. Cell Res. 1994, 213:148-155.
79. Mason D.X., et al. Molecular signature of oncogenic ras-induced senescence. Oncogene 2004, 23:9238-9246.
80. Shelton D.N., et al. Microarray analysis of replicative senescence. Curr. Biol. 1999, 9:939-945.
81. Kuilman T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
82. Coppe J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
83. Chien Y., et al. Control of the senescence-associated secretory phenotype by NF-{kappa}B promotes senescence and enhances chemosensitivity. Genes Dev. 2011, 25:2125-2136.
84. Jing H., et al. Opposing roles of NF-{kappa}B in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011, 25:2137-2146.
85. Krtolica A., et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12072-12077.
86. Parrinello S., et al. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci. 2005, 118:485-496.
87. Coppe J.P., et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 2006, 281:29568-29574.
88. Kortlever R.M., et al. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 2006, 8:877-884.